D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results

Li, Ziming; Song, Zhengbo; Zhao, Yanqiu; Wang, Pingli; Jiang, Liyan; Gong, Yi; Zhou, Jianying; Jian, Hong; Dong, Xiaorong; Zhuang, Wu; Cang, Shundong; Yang, Nong; Fang, Jian; Shi, Jianhua; Lu, Junguo; Ma, Rui; Wu, Ping; Zhang, Yingqian; Song, Mengmeng; Xu, Chun-Wei; Shi, Zhe; Zhang, Ling; Wang, Yaolin; Wang, Xicheng; Zhang, Yiping; Lu, Shun

doi:10.1016/j.jtho.2023.03.015

D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results

INTRODUCTION D-1553 (garsorasib) is a potent and selective oral KRASG12C inhibitor. We report results from a phase I dose-escalation/dose-expansion study of D-1553 in patients with KRAS G12C-mutated NSCLC in multiple sites of China. METHODS Patients with KRAS G12C-mutated NSCLC were administrated…